Dry eyedisease compounds…
157
linoleic (LA) and gamma-‐linolenic acid (GLA) are reducing eye inflammation, and
n-‐6 pathway eicosanoids are considered as promoting inflammation (32, 33).
Omega-‐3 and omega-‐6 EFAs are used for dry eye treatment due to their anti-‐
inflammatory effects such as the drug
Nutrilarm
® of the French company Théa
Laboratoires, which is already commercialized in Europe. This medicine uses a
supplementation of omega-‐3 and omega-‐6 fatty acids, which according to the
company reduce expression of the conjunctival inflammatory marker human
leucocyte antigen-‐DR (HLA-‐DR) and may help improving DED symptoms. The
compound past in 2006 from Phase II clinical trials in US (ClinicalTrials.gov
Identifier: NCT00357201) but the company decided to continue the pre-‐clinical
development toresolveefficacyanddoses issues (34-‐36).
ORALOMEGA-‐3-‐ACIDETHYLESTERS
Pennsylvania State University and the American Society of Cataract and
Refractive Surgery Foundation (ClinicalTrials.gov Identifier: NCT01107964)
started in April 2010 a clinical study, based on the hypothesis that oral omega-‐3-‐
acid ethyl esters (Lovaza, GlaxoSmithKline) will decrease the dry-‐eye related
symptoms as well as clinical markers associated to dry eye disease. The
preliminary results of the study arepositivebutmore research is needed todefine
thecompositionanddosingof the treatment. Fromtheresults itwas confirmed the
relationship between EFA supplementation and improvement in dry eye
symptoms in patients (37). Nevertheless before any anti-‐inflammatory therapy is
necessary a detailed examination of a patient due to the complexity of the disease
andtoprovide individual andsuccessful treatment (38).
SECUKINUMABANDCANAKINUMAB
Novartis Pharmaceuticals Inc.
presented two novel antibodies,
Secukinumab (AIN457) and Canakinumab (ACZ885). Secukinumab is a fully
humanmonoclonal antibodydesigned tobind selectively, inhibiting thememberA
of interleukin 17cytokine family, a key driver of immune-‐mediated diseases.
Canakinumab is a fully humanmonoclonal antibody, inhibiting solely interleukin
1β (IL-‐1β), the formof the interleukin-‐1 protein that is themain cause of various
inflammatory diseases (39). Currently both antibodies are under development as
treatments of a wide range of auto inflammatory diseases. In November 2010
Novartis started a Phase II study on effects of a single intravenous administration
of Secukinumab 10 mg/kg or Canakinumab 10 mg/kg on 72 dry eye patients
